To markedly decrease tumor growth in TNBC and avoid potential toxicity associated with high dosages in humans, it could be interesting to use the GRP94 inhibitor in combination with/or before an immune checkpoint inhibitor, such as anti-PD-L1 antibodies, which are already used in clinics and in several clinical trials in TNBC [49]. This evidence concerns the gene CD274 and neoplasm.